72 related articles for article (PubMed ID: 22154379)
21. [Development of binding antibodies to interferon-beta during treatment of multiple sclerosis with different types of interferon-beta].
Bartosik-Psujek H; Mitosek-Szewczyk K; Belniak E; Stelmasiak Z
Pol Merkur Lekarski; 2004 Jul; 17(97):28-32. PubMed ID: 15559606
[TBL] [Abstract][Full Text] [Related]
22. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
Hurwitz BJ
J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
[TBL] [Abstract][Full Text] [Related]
23. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
[TBL] [Abstract][Full Text] [Related]
24. Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis.
Foley P; Reilly P; Coulson A; O'Riordan JI
J R Coll Physicians Edinb; 2010 Jun; 40(2):105-10. PubMed ID: 21125049
[TBL] [Abstract][Full Text] [Related]
25. Influence of the maillard reaction to prion protein aggregation.
Panza G; Dumpitak C; Birkmann E
Rejuvenation Res; 2010; 13(2-3):220-3. PubMed ID: 20370497
[TBL] [Abstract][Full Text] [Related]
26. Concentrations of receptor for advanced glycation end products, VEGF and CML in plasma, follicular fluid, and peritoneal fluid in women with and without endometriosis.
Fujii EY; Nakayama M; Nakagawa A
Reprod Sci; 2008 Dec; 15(10):1066-74. PubMed ID: 19088375
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of four different assays for the detection of binding antibodies against interferon-beta.
Gneiss C; Brugger M; Millonig A; Fogdell-Hahn A; Rudzki D; Hillert J; Berger T; Reindl M; Deisenhammer F
Mult Scler; 2008 Jul; 14(6):830-6. PubMed ID: 18535018
[TBL] [Abstract][Full Text] [Related]
28. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
29. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
Sorensen PS; Koch-Henriksen N; Bendtzen K
Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
[TBL] [Abstract][Full Text] [Related]
30. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
[TBL] [Abstract][Full Text] [Related]
31. Neutralising antibodies to interferon-beta therapy in relapsing multiple sclerosis: a pilot study.
Lau AYL; Chan E; Lau KK; Mok V; Siu DYW; Lee R
Hong Kong Med J; 2019 Aug; 25 Suppl 5(4):22-25. PubMed ID: 31416982
[No Abstract] [Full Text] [Related]
32. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
33. Characterization of anti-advanced glycation end product antibodies to nonenzymatically lysine-derived and arginine-derived glycated products.
Choi YG; Lim S
J Immunoassay Immunochem; 2009; 30(4):386-99. PubMed ID: 19739013
[TBL] [Abstract][Full Text] [Related]
34. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b.
Speciale L; Saresella M; Caputo D; Ruzzante S; Mancuso R; Calvo MG; Guerini FR; Ferrante P
J Neurovirol; 2000 May; 6 Suppl 2():S57-61. PubMed ID: 10871787
[TBL] [Abstract][Full Text] [Related]
35. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
36. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
[TBL] [Abstract][Full Text] [Related]
37. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis.
Koch M; Mostert J; De Keyser J; Tremlett H; Filippini G
Ann Neurol; 2008 Jan; 63(1):125-6; author reply 126-7. PubMed ID: 17702024
[No Abstract] [Full Text] [Related]
38. Antibodies against interferon-beta in multiple sclerosis.
Aarskog NK; Marøy T; Myhr KM; Vedeler CA
J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
[TBL] [Abstract][Full Text] [Related]
39. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
40. Rational selection of an antibody probe to detect the heterogeneous collection of CHO-derived rhGM-CSF glycoforms.
Oggero M; Forno G; Kratje R; Etcheverrigaray M
Biotechnol Lett; 2006 Dec; 28(24):2049-56. PubMed ID: 17004006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
